Trametinib (3) (Mekinist®) – Melanoma, in combination with dabrafenib, BRAF V600 mutation, adjuvant therapy

Characteristics

Start date 01.10.2018
Resolution 22.03.2019
Limitation date 01.04.2024 limitation repealed
INN Trametinib
Brand name Mekinist®
Pharm. company Novartis Pharma GmbH
G-BA procedure ID 2018-10-01-D-384
ATC code L01XE25
DDD 2 mg O
Therapeutic area Oncological diseases
Reason for procedure New Indication
Specialty Special practice conditions

Indication (German)

Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

Subpopulation Indication Comparator
In combination with dabrafenib for the adjuvant treatment of adult stage III melanoma patients with a BRAF V600 mutation after complete resection. Observational waiting

9. Associated procedures



<< List of all resolutions